Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome

Completed · Phase 3

Conditions studied: Zollinger-Ellison Syndrome

In brief

This research study will determine if esomeprazole, when administered twice daily at 40, 80, or 120 mg doses, can control excessive stomach acid secretion.

Key facts

Study ID

NCT00079833

Run by

AstraZeneca

People needed

25

Starts

2003-11-01

Expected to finish

2005-07-01

Last updated by the study team

2010-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females at least 18 years of age.
• Diagnosis of Zollinger-Ellison Syndrome or idiopathic hypersecretion

You may not qualify if…

• Pregnant or lactating females
• History of drug addiction or alcohol abuse within 12 months prior to Screening.
• History of intolerance to any proton pump inhibitors or any ingredient in their formulation.

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Columbus, Ohio, United States
• Research Site — King of Prussia, Pennsylvania, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Clichy, France
• Research Site — Paris, France
• Research Site — Saint-Germain-en-Laye, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.